Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study.

"Declarations Ethics approval and consent to participateThe study protocol was reviewed and approved by the Ethical Clearance Committee on Human Right Related to Research Involving Human Subjects of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (MURA2014/18). Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by Dr Prasert Prasarttong-Osoth Research Grant from the Medical Association of Thailand. The funding body had no role in the study design, data collection, analysis and interpretation and in writing the manuscript."

"This study is a substudy of a randomized, double-blind, crossover study of 24 HIV-infected dyslipidemic patients receiving ritonavir boosted atazanavir (ATV/r) that was conducted to study safety and efficacy of pitavastatin for treatment of dyslipidemia (ClinicalTrials.gov NCT02442700) []. Breifly, participants were assigned to receive 2 mg/day of pitavastatin or placebo for 12 weeks, followed by 2 weeks of washout period, and then 12 weeks of the other treatment arm (Fig. ). At the enrollment and at the end of 12 weeks of each treatment arm, blood was collected for inflammatory marker study. Estimated 10-year cardiovascular disease risk was calculated by Thai CV risk score, a tool developed to predict a 10 year cardiovascular risk using data from Thai people, as recommended by Thai guidelines [, ] (Application available on App store: https://apps.apple.com/id/app/thai-cv-risk-calculator/id1564700992).Fig. 1Flowchart of subjects in the randomized crossover trial"